Citadel Advisors’s PAVmed Inc. Series Z Warrant PAVMZ Stock Holding History

Citadel Advisors’s Portfolio PAVMZ Stock Details PAVMZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-41,721	Closed	-$234	–	15738
2025 Q1	$234	Sell	41,721 -1,171	-3%	-$11	﹤0.01%	14305
2024 Q4	$425	Buy	42,892 +200	+0.5%	+$4	﹤0.01%	14326
2024 Q3	$918	Buy	42,692 +484	+1%	+$15	﹤0.01%	13936
2024 Q2	$844	Buy	+42,208	New	+$1.61K	﹤0.01%	13903
2023 Q3	–	Sell	-19,982	Closed	-$3.2K	–	15294
2023 Q2	$3.2K	Buy	+19,982	New	+$2.58K	﹤0.01%	13709

Citadel Advisors's PAVMZ Position: Q2 2025 in Review

Citadel Advisors sold out of PAVmed Inc. Series Z Warrant (PAVMZ) in Q2 2025, closing a stake of 41,721 shares — an estimated $234 sold.

Citadel Advisors first reported a position in PAVMZ in Q2 2023 and held it in 5 quarters. The position peaked at $3.2K in Q2 2023. 0 funds tracked by Wall St. Rank hold PAVMZ as of Q2 2025.

Citadel Advisors reported no remaining PAVmed Inc. Series Z Warrant position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 41,721 PAVmed Inc. Series Z Warrant shares in Q2 2025, an estimated $234.
Citadel Advisors first reported a position in PAVmed Inc. Series Z Warrant in Q2 2023 and held it in 5 quarters.
Citadel Advisors's PAVmed Inc. Series Z Warrant position peaked at $3.2K in Q2 2023.
0 funds tracked by Wall St. Rank held PAVmed Inc. Series Z Warrant as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.